Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Semiology and Mechanisms of Near-Death Experiences

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Susacs syndrom er en vigtig differentialdiagnose ved monosymptomatisk encefalopati hos yngre voksne.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes.

METHODS: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders.

RESULTS: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively.

CONCLUSIONS: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.

OriginalsprogEngelsk
TidsskriftBMC Psychiatry
Vol/bind17
Udgave nummer1
Sider (fra-til)161
ISSN1471-244X
DOI
StatusUdgivet - 2017

ID: 52426187